open access

Vol 1, No 4 (2005)
Review paper
Published online: 2005-12-12
Get Citation

The role of EGFR tyrosine kinase inhibitors in the treatment of non-small cell lung cancer

Anna Kowalczyk, Ewa Szutowicz-Zielińska, Rafał Dziadziuszko, Jacek Jassem
Onkol. Prak. Klin 2005;1(4):217-224.

open access

Vol 1, No 4 (2005)
REVIEW ARTICLES
Published online: 2005-12-12

Abstract

Lung cancer is the leading cause of cancer related death. The results of treatment of advanced lung cancer are poor. The EGFR tyrosine kinase inhibitors (erlotinib and gefitinib) provide a new treatment option for patients with locally advanced lung cancer. In phase II clinical trials with both gefitinib and erlotonib in second or third line chemotherapy, promising response rates and cancer related symptoms relief were found. However, out of 6 randomized trials with tyrosine kinase inhibitors, only one revealed the improvement of overall survival. So minimal effect of tyrosine kinase inhibitors most likely reflected the lack of appropriate inclusion criteria. Conducted molecular and clinical studies showed clinical benefit mostly in patients with EGFR tyrosine kinase domain mutation. These mutations are present in 10% of non small cell lung cancer, more frequently in women, Asian rase, non-smokers and adenocarcinoma and bronchioalveolar cancer. These are ongoing studies focused on finding optimal criteria for the use of tyrosine kinase inhibitors in patients with non small cell lung cancer.

Abstract

Lung cancer is the leading cause of cancer related death. The results of treatment of advanced lung cancer are poor. The EGFR tyrosine kinase inhibitors (erlotinib and gefitinib) provide a new treatment option for patients with locally advanced lung cancer. In phase II clinical trials with both gefitinib and erlotonib in second or third line chemotherapy, promising response rates and cancer related symptoms relief were found. However, out of 6 randomized trials with tyrosine kinase inhibitors, only one revealed the improvement of overall survival. So minimal effect of tyrosine kinase inhibitors most likely reflected the lack of appropriate inclusion criteria. Conducted molecular and clinical studies showed clinical benefit mostly in patients with EGFR tyrosine kinase domain mutation. These mutations are present in 10% of non small cell lung cancer, more frequently in women, Asian rase, non-smokers and adenocarcinoma and bronchioalveolar cancer. These are ongoing studies focused on finding optimal criteria for the use of tyrosine kinase inhibitors in patients with non small cell lung cancer.
Get Citation

Keywords

gefitinib; erlotinib; non-small cell lung cancer; targeted therapy

About this article
Title

The role of EGFR tyrosine kinase inhibitors in the treatment of non-small cell lung cancer

Journal

Oncology in Clinical Practice

Issue

Vol 1, No 4 (2005)

Article type

Review paper

Pages

217-224

Published online

2005-12-12

Bibliographic record

Onkol. Prak. Klin 2005;1(4):217-224.

Keywords

gefitinib
erlotinib
non-small cell lung cancer
targeted therapy

Authors

Anna Kowalczyk
Ewa Szutowicz-Zielińska
Rafał Dziadziuszko
Jacek Jassem

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl